Litigation Details for In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES. (D. Kan. 2017)
✉ Email this page to a colleague
In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES. (D. Kan. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-08-04 |
| Court | District Court, D. Kansas | Date Terminated | |
| Cause | 28:1407 Multi-District Litigation | Assigned To | Daniel Dale Crabtree |
| Jury Demand | Both | Referred To | |
| Patents | 7,449,012; 7,794,432 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES. (D. Kan. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-08-20 | 896 | Order on Motion to Dismiss | Meridian—sued Teva for infringing U.S. Patent No. 7,449,012 (“the Teva Litigation”). In November 2010…Defendants did so by adding several more patents to the already-patented EpiPen to prevent the launch of competing…2009 that Mylan was adding another patent to the already-patented EpiPen device that “will also put in… ’432 patent. Later, King and Meridian dropped their claims based on infringing the ’012 patent, leaving…that Intelliject’s EAI infringed the ’432 patent—a patent that Meridian secured more than a year after | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
